Compare Interactive Brokers Group Inc. Class A Common Stock (IBKR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Interactive Brokers Group Inc. Class A Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Interactive Brokers Group Inc. Class A Common Stock trades at $84.15 (market cap $38.14B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Interactive Brokers Group Inc. Class A Common Stock is far larger — about 39× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Interactive Brokers Group Inc. Class A Common Stock pays a 0.42% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Interactive Brokers Group Inc. Class A Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IBKR | MRVI | |
|---|---|---|
Market Cap | $38.14B | $977.37M |
Volume | 4,556,837 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $98.19 | $9.00 |
52-Week Low | $61.05 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.44B | $1.08B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Interactive Brokers (IBKR) trades at $87.49, down 0.46% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The company demonstrates strong fundamentals with revenue growth from $10.22B in 2025 to $11.1B projected for 2026, and net income rising from $984M to $1.1B. Recent earnings beats and expansion into cryptocurrency staking highlight ongoing business development, though valuation multiples appear elevated with a P/E of 34.72.
The outlook remains cautiously optimistic given analyst consensus pointing to 21% upside to the $106.11 price target, balanced by near-term technical weakness and stretched valuations. Key risks include competitive pressures in fintech and market volatility impacting trading volumes, while institutional sentiment shows mixed but generally positive positioning with 47% buy ratings.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Interactive Brokers Group Inc. Class A Common Stock
Interactive Brokers operates an electronic brokerage platform for trading stocks, options, futures, currencies, and other assets. It also provides clearing and custody services.
Read more on IBKR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
